NYSE:ORGSOrgenesis Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.86 -0.02 (-0.29 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$6.86Now: $6.86▼$7.1850-Day Range$4.16MA: $5.68▼$7.2852-Week Range$2.35Now: $6.86▼$8.20Volume34,400 shsAverage Volume82,518 shsMarket Capitalization$150.89 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsHeadlinesSocial Media Orgenesis Inc., a service and research company, focus on the development and manufacture of cell therapy for advanced medicinal products in the field of regenerative medicine industry. It operates through two segments, Contract Development and Manufacturing Organizations (CDMO) and Cellular Therapy (CT) Business. The CDMO segment specializes in cell therapy development for advanced medicinal products. This segment provides process and assay development services; and current Good Manufacturing Practices contract manufacturing services. The CT Business segment develops cell trans-differentiation technology induce shift in the developmental fate of cells from the liver and differentiating them into pancreatic beta cell-like insulin producing cells for patients with Type 1 diabetes. The company has a collaboration agreement with CureCell Co., Ltd. to carry out pre-clinical and clinical activities related to the commercialization of autologous insulin producing cell therapy product in Korea; and with BGN Technologies and the National Institute for Biotechnology to develop and commercialize a scaffold technology for cell transplantation, as well as a collaboration and license agreement with Mircod Limited for the research, development, and commercialization of various technologies related to biological sensing for Orgenesis's clinical development and manufacturing projects. It also has a collaboration agreements with Ben-Gurion University and MangoGen Pharma Inc. The company was formerly known as Business Outsourcing Services, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was founded in 2008 and is based in Germantown, Maryland.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Orgenesis. Previous Next 2.2 Community Rank Outperform VotesOrgenesis has received 20 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOrgenesis has received 25 “underperform” votes. (Add your “underperform” vote.)Community SentimentOrgenesis has received 55.56% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Orgenesis and other stocks. Vote “Outperform” if you believe ORGS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ORGS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOrgenesis does not currently pay a dividend.Dividend GrowthOrgenesis does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Orgenesis insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.44 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSE:ORGS Previous Symbol CUSIPN/A CIKN/A Webwww.orgenesis.com Phone480-659-6404Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares21,996,000Market Cap$150.89 million Next Earnings DateN/A OptionableNot Optionable ORGS Rates by TradingView Receive ORGS News and Ratings via Email Sign-up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter. Orgenesis (NYSE:ORGS) Frequently Asked Questions How has Orgenesis' stock been impacted by COVID-19 (Coronavirus)? Orgenesis' stock was trading at $3.86 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ORGS stock has increased by 77.7% and is now trading at $6.86. View which stocks have been most impacted by Coronavirus. How were Orgenesis' earnings last quarter? Orgenesis Inc. (NYSE:ORGS) posted its quarterly earnings results on Tuesday, March, 10th. The company reported ($0.42) earnings per share for the quarter. The company earned $9.08 million during the quarter. View Orgenesis' earnings history. Has Orgenesis been receiving favorable news coverage? Press coverage about ORGS stock has been trending very negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Orgenesis earned a news impact score of -3.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an effect on the company's share price in the immediate future. View the latest news aboutOrgenesis. Who are some of Orgenesis' key competitors? Some companies that are related to Orgenesis include Medicenna Therapeutics (MDNA), ProMetic Life Sciences (PLI), IMV (IMV), Emblem (EMC), Pfenex (PFNX), Exicure (XCUR), Fennec Pharmaceuticals (FRX), Bioventix (BVXP), Novacyt (NCYT), Theratechnologies (TH), Exicure (XCUR), Enochian Biosciences (ENOB), Antibe Therapeutics (ATE), IMV (IMV) and Ergomed (ERGO). View all competitors. What other stocks do shareholders of Orgenesis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Orgenesis investors own include China Pharma (CPHI), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Adverum Biotechnologies (ADVM), Adient (ADNT), Adaptimmune Therapeutics (ADAP), AcelRx Pharmaceuticals (ACRX), Aclaris Therapeutics (ACRS), ACM Research (ACMR) and Achillion Pharmaceuticals (ACHN). Who are Orgenesis' key executives? Orgenesis' management team includes the following people: Ms. Vered Caplan, Chairman, CEO & Pres (Age 49)Prof. Sarah Ferber, Founder & Chief Scientific Officer (Age 64)Mr. Neil T. Reithinger, CFO, Sec. & Treasurer (Age 48)Dr. Denis Bedoret, Gen. Mang. of MaSTHERCELL (Age 37) What is Orgenesis' stock symbol? Orgenesis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ORGS." How do I buy shares of Orgenesis? Shares of ORGS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Orgenesis' stock price today? One share of ORGS stock can currently be purchased for approximately $6.86. How big of a company is Orgenesis? Orgenesis has a market capitalization of $150.89 million. What is Orgenesis' official website? The official website for Orgenesis is www.orgenesis.com. How can I contact Orgenesis? The company can be reached via phone at 480-659-6404. This page was last updated on 5/29/2020 by MarketBeat.com Staff
